Plk1 Inhibitors in Cancer Therapy: From Laboratory to Clinics.

@article{Gutteridge2016Plk1II,
  title={Plk1 Inhibitors in Cancer Therapy: From Laboratory to Clinics.},
  author={Rosie Elizabeth Ann Gutteridge and Mary Ann Ndiaye and X John{\'e} Liu and Nihal Ahmad},
  journal={Molecular cancer therapeutics},
  year={2016},
  volume={15 7},
  pages={1427-35}
}
Polo-like kinase 1 (Plk1) overexpression has been shown to occur in a wide range of tumors, prompting research and development of Plk1 inhibitors as a means of cancer treatment. This review discusses recent advances in the development of Plk1 inhibitors for cancer management. Plk1 inhibition has been shown to cause mitotic block and apoptosis of cells with higher mitotic index and therefore higher Plk1 expression. The potential of Plk1 inhibitors as cancer therapeutics has been widely… CONTINUE READING
Recent Discussions
This paper has been referenced on Twitter 1 time over the past 90 days. VIEW TWEETS